For example, TP53 mutations are present in 89–92% of SCLC cases [8, 9] and are strongly associated with treatment resistance, tumor heterogeneity, and disease progression in both SCLC and NEPC [1, 10, 11]. This evidence concerns the gene TP53 and small cell lung carcinoma.